Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: A study from the French society of bone marrow transplantation and French study group on Cutaneous Lymphomas

Haematologica

Volumn 99, Issue 3, 2014, Pages 527-534

  de Masson, Adèle ^a   Beylot Barry, Marie ^b   Bouaziz, Jean David ^a   de Latour, Régis Peffault ^a   Aubin, François ^c   Garciaz, Sylvain ^d   D'Incan, Michel ^e   Dereure, Olivier ^f   Dalle, Stéphane ^g   Dompmartin, Anne ^h   Suarez, Felipe ⁱ   Battistella, Maxime ^j   Vignon Pennamen, Marie Dominique ^a   Rivet, Jacqueline ^j   Adamski, Henri ^k   Brice, Pauline ^j   François, Sylvie ^l   Lissandre, Séverine ^m   Turlure, Pascal ⁿ   Wierzbicka Hainaut, Ewa ^o   Brissot, Eolia ^p   Dulery, Rémy ^q   Servais, Sophie ^r   Ravinet, Aurélie ^e   Tabrizi, Reza ^s   Ingen Housz Oro, Saskia ^t   Joly, Pascal ^u   Socié, Gérard ^a   Bagot, Martine ^a   more..

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF BESANÇON   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^f HÔPITAL SAINT ELOI   (France)

^g CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^h CAEN UNIVERSITY HOSPITAL   (France)

ⁱ HÔPITAL NECKER ENFANTS MALADES   (France)

^j SAINT LOUIS HOSPITAL   (France)

^k PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^l ANGERS UNIVERSITY HOSPITAL   (France)

^m UNIVERSITY HOSPITAL OF TOURS   (France)

ⁿ LIMOGES UNIVERSITY HOSPITAL   (France)

^o POITIERS UNIVERSITY HOSPITAL   (France)

^p NANTES UNIVERSITY HOSPITAL   (France)

^q LILLE UNIVERSITY HOSPITAL   (France)

^r UNIVERSITY OF LIÈGE   (Belgium)

^s HAUT LÉVÊQUE HOSPITAL   (France)

^t HENRI MONDOR HOSPITAL   (France)

^u HÔPITAL CHARLES NICOLLE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CARMUSTINE; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PENTOSTATIN; RETINOID; THYMOCYTE ANTIBODY;

ADENOVIRUS INFECTION; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CANDIDIASIS; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS T CELL LYMPHOMA; DISEASE CLASSIFICATION; DISEASE COURSE; ENGRAFTMENT; ERYTHEMA; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HISTOLOGY; HUMAN; IMMUNOPHENOTYPING; MALE; MORTALITY; MULTICENTER STUDY; MYCOSIS FUNGOIDES; OVERALL SURVIVAL; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEZARY SYNDROME; SKIN LYMPHOMA; WHOLE BODY RADIATION; ADVERSE EFFECTS; ALLOTRANSPLANTATION; CANCER STAGING; DONOR; FRANCE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA, T-CELL, CUTANEOUS; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FRANCE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; NEOPLASM STAGING; RECURRENCE; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84895727587     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.098145     Document Type: Article

References (27)

1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-85.
2. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-22.
3. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730-9.
4. Vergier B, de Muret A, Beylot-Barry M, Vaillant L, Ekouevi D, Chene G, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood. 2000;95 (7):2212-8.
5. Arulogun SO, Prince HM, Ng J, Lade S, Ryan GF, Blewitt O, et al. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood. 2008;112(8):3082-7.
6. Ingen-Housz-Oro S, Bachelez H, Verola O, Lebbé C, Marolleau JP, Hennequin C, et al. High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma. Bone Marrow Transplant. 2004;33(6):629-34.
7. Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten WA, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95(12):3653-61.
8. Herbert KE, Spencer A, Grigg A, Ryan G, McCormack C, Prince HM. Graft-versuslymphoma effect in refractory cutaneous Tcell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;34(6):521-5.
9. Molina A, Zain J, Arber DA, Angelopolou M, O'Donnell M, Murata-Collins J, et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol. 2005;23(25):6163-71.
10. Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol. 2010;28(14):2365-72.
11. Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28(29):4492-9.
12. Duarte RF, Schmitz N, Servitje O, Sureda A. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant. 2008;41(7):597-604.
13. Paralkar VR, Nasta SD, Morrissey K, Smith J, Vassilev P, Martin ME, et al. Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas. Bone Marrow Transplant. 2012;47(7):940-5.
14. Carrié E, Buzyn A, Fraitag S, Hermine O, Bodemer C. [Transformed juvenile-onset mycosis fungoides: treatment by bone marrow transplantation with graft-versus-lymphoma effect]. Ann Dermatol Venereol. 2007;134(5 Pt 1):471-6.
15. Terras S, Moritz RKC, Ditschkowski M, Beelen DW, Altmeyer P, Stücker M, et al. Allogeneic Haematopoietic Stem Cell Transplantation in a Patient with Cutaneous γ/δ-T-cell Lymphoma. Acta Derm Venereol. 2013;93(3):360-1.
16. Yuan L, Sun L, Bo J, Zhou Y, Li H, Yu L, et al. Durable remission in a patient with refractory subcutaneous panniculitis-like Tcell lymphoma relapse after allogeneic hematopoietic stem cell transplantation through withdrawal of cyclosporine. Ann Transplant. 2011;16(3):135-8.
17. Pérez-Persona E, Mateos-Mazón JJ, López-Villar O, Arcos MJ, Encinas C, Graciani IF, et al. Complete remission of subcutaneous panniculitic T-cell lymphoma after allogeneic transplantation. Bone Marrow Transplant. 2006;38(12):821-2.
18. Fijnheer R, Sanders CJG, Canninga MR, de Weger RA, Verdonck LF. Complete remission of a radiochemotherapy-resistant cutaneous T-cell lymphoma with allogeneic non-myeloablative stem cell transplantation. Bone Marrow Transplant. 2003;32(3):345-7.
19. Ohmatsu H, Sugaya M, Fujita H, Kadono T, Sato S. Primary Cutaneous Follicular Helper T-cell Lymphoma Treated with Allogeneic Bone Marrow Transplantation: Immunohistochemical Comparison with Angioimmunoblastic T-cell Lymphoma. Acta Derm Venereol. 2013 June 5 [Epub ahead of print].
20. Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(2):479-84.
21. Poszepczynska-Guigné E, Schiavon V, D'Incan M, Echchakir H, Musette P, Ortonne N, et al. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome. J Invest Dermatol. 2004; 122(3):820-3.
22. Bouaziz J-D, Remtoula N, Bensussan A, Marie-Cardine A, Bagot M. Absolute CD3+ CD158k+ lymphocyte count is reliable and more sensitive than cytomorphology to evaluate blood tumour burden in Sézary syndrome. Br J Dermatol. 2010;162(1):123-8.
23. Bensussan A, Remtoula N, Sivori S, Bagot M, Moretta A, Marie-Cardine A. Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sézary syndrome patients. J Invest Dermatol. 2011;131(4):969-76.
24. Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598-607.
25. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant. 2007; 40(4):381-7.
26. Dummer R, Quaglino P, Becker JC, Hasan B, Karrasch M, Whittaker S, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol. 2012;30 (33):4091-7.
27. Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, et al. Graftversus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2013;31(12): 1530-8.